Katie V. Tieu

Katie V. Tieu

Auto-generated profile, based on publicly available information

Katie V. Tieu

Department of Biomedical Engineering, Virginia Commonwealth University, Richmond, Virginia, United States of America

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 August 2020 in bioRxiv
Verified
Preprint
Open access
PDF file
KRKenneth Risner
Kenneth Risner
KTKatie V. Tieu
Katie V. Tieu
YWYafei Wang
Yafei Wang
Allison BakovicAllison Bakovic
Allison Bakovic
FAFarhang Alem
Farhang Alem
ANAarthi Narayanan
Aarthi Narayanan
In an effort to identify therapeutic intervention strategies for the treatment of COVID-19, we have investigated a selection of FDA-approved small molecules and biologics that are commonly used to treat other human diseases. A investigation into 18 small molecules and 3 biologics was conducted in cell culture and the impact of treatment on viral titer was quantified by plaque assay. The investigation identified 4 FDA-approved small molecules, Maraviroc, FTY720 (Fingolimod), Atorvastatin and Nitazoxanide that were able to inhibit SARS-CoV-2 infection. Confocal microscopy with over expressed S-protein demonstrated that Maraviroc reduced the extent of S-protein mediated cell fusion as observed by fewer multinucleate cells in the context of drugtreatment. Mathematical modeling of drug-dependent viral multiplication dynamics revealed that prolonged drug treatment will exert an exponential decrease in viral load in a multicellular/tissue environment. Taken together, the data demonstrate that Maraviroc, Fingolimod, Atorvastatin and Nitazoxanide inhibit SARS-CoV-2 in cell culture.

1 January 2020 in Nucleus
Verified
Journal Article
Open access
BDBrooke E. Danielsson
Brooke E. Danielsson
KTKatie V. Tieu
Katie V. Tieu
KBKranthidhar Bathula
Kranthidhar Bathula
TATravis J. Armiger
Travis J. Armiger
PVPragna S. Vellala
Pragna S. Vellala
DCDaniel Conway
Daniel Conway
The nuclear lamina is a meshwork of intermediate filament proteins, and lamin A is the primary mechanical protein. An altered splicing of lamin A, known as progerin, causes the disease Hutchinson-Gilford progeria syndrome. Progerin-expressing cells have altered nuclear shapes and stiffened nuclear lamina with microaggregates of progerin. Here, progerin microaggregate inclusions in the lamina are shown to lead to cellular and multicellular dysfunction. We show with Comsol simulations that stiffened inclusions causes redistribution of normally homogeneous forces, and this redistribution is dependent on the stiffness difference and relatively independent of inclusion size. We also show mechanotransmission changes associated with progerin expression in cells under confinement and cells under external forces. Endothelial cells expressing progerin do not align properly with patterning. Fibroblasts expressing progerin do not align properly to applied cyclic force. Combined, these studies show that altered nuclear lamina mechanics and microstructure impacts cytoskeletal force transmission through the cell.